CN-201

N/A

Report date: 2026/05/22 20:01:29

Base Information

Drug NameCN-201
Drug Alias NameCN-201MK-1045
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD19Anti-CD3
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, Follicular +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumRomaniaItaly +[8] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesCuron Biopharmaceutical Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTongrun Bio-pharmaceutical (Shanghai) Co LtdCuron Biopharmaceutical LtdMerck Sharp & Dohme LLC +[4] 
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicArthritis, RheumatoidLymphoma, Follicular +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A